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NOCTURNAL HYPOGLYCEMIA – THE MAIN INDICATION 
FOR INSULIN PUMP THERAPY IN ADULTHOOD
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SUMMARY – The aim was to determine which adult type 1 diabetic patient receiving multiple 
daily injection therapy is the most appropriate candidate for insulin pump therapy, while taking into 
consideration limited insulin pump affordability in Croatia. A total of 145 type 1 diabetic patients 
(52% diagnosed in adult age) were monitored at the Department of Endocrinology, Clinical De-
partment of Internal Medicine, Zagreb University Hospital Center from 2009 to 2014. Twenty-one 
patients started insulin pump therapy in adulthood (seven men and 14 women, median age 27). Five 
patients had chronic complications (retinopathy in two, polyneuropathy in one, and both nephro-
pathy and retinopathy in two patients). The median HbA1c at the initiation of pump therapy was 
6.95% versus 6.5% after 1 year of pump therapy. Patients were stratified according to indications for 
insulin pump therapy (frequent and/or severe hypoglycemia, specific lifestyle, having not reached 
glycemic goals despite adherence/labile diabetes, and preconception). Patients could meet more than 
one criterion. Initially, the occurrence of hypoglycemia was analyzed by 6-day continuous glucose 
monitoring, while re-evaluation was done after collecting history data at 1 year ± 3 months. Initially, 
all patients had a median of 5 hypoglycemias/6 days (30% nocturnal) versus 1 hypoglycemia/6 days 
(without nocturnal) after 1 year. The Wilcoxon signed-rank test yielded a statistically significant di-
fference in hypoglycemic events, nocturnal hypoglycemia and HbA1c. Patients commencing insulin 
pump therapy due to hypoglycemia initially had median HbA1c of 6.7% with 7 hypoglycemia/6 
days (50% nocturnal). After one year, median HbA1c was 6% with 1 hypoglycemia/6 days (without 
nocturnal). In conclusion, the main indication for insulin pump therapy in adults is the frequency of 
hypoglycemia, especially nocturnal ones. 
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Introduction
According to the most recent report of the Croatian 
National Institute of Public Health from 2013, there 
were 241,990 adult persons suffering from diabetes 
registered with their general practitioners.  Of these 
cases, 6.96% were classified as type 11. The Interna-
tional Diabetes Federation (IDF)-Europe Access sur-
vey conducted in Croatia showed that most patients 
treated with insulin were using insulin analogues and 
insulin pens. This type of therapy is available across 
the country2. Only 611 patients with type 1 diabetes 
in Croatia were treated with insulin pumps, of which 
384 were children and 227 adults (data from the sole 
distributor as of October 2014). The survey2 claims 
that the use of insulin pumps in Croatia is limited, 
and that the pumps are more widely available in the 
capital than in other areas. They are primarily given to 
children and pregnant women. 
Type 1 diabetes is a condition where insulin re-
placement therapy is life-saving. The standard basal-
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bolus treatment administering multiple daily injec-
tions is sometimes associated with practical problems 
and requires an alternative solution. The use of insulin 
pump moderately improves glycemic control as re-
vealed in meta-analyses3,4, as well as in multicenter ob-
servational studies5. Patients that do not reach glyce-
mic goals despite being compliant with multiple daily 
injections or have problems such as too frequent or 
unrecognized hypoglycemia, i.e. dawn phenomenon, 
are candidates for continuous subcutaneous insulin in-
fusion (CSII), e.g., insulin pumps. Those who exhibit 
allergy to prolonged acting insulin are also candidates 
for CSII6. There is no strict evidence that CSII treat-
ment in pregnancy is superior to a multiple injection 
regimen in lowering hypoglycemia rates (lack of ran-
domized trials). Though, it is clear that patient satisfac-
tion is an acceptable indication for pump therapy dur-
ing pregnancy7. Beyond childhood, preconception and 
pregnancy, the indications for insulin pump are brittle 
diabetes with many glycemic excursions, frequent 
severe hypoglycemia and/or hypoglycemia unaware-
ness, dawn phenomenon, high insulin sensitivity and a 
specific lifestyle (e.g., shift work, travel and sports). A 
small observational study confirmed the beneficial ef-
fect of CSII in post-exercise hypoglycemia8. Not every 
patient showing the mentioned indications is suitable 
for this kind of demanding and sophisticated technol-
ogy. Selecting an optimal candidate is not easy, espe-
cially when the number of devices is limited. Although 
there are no published local guidelines, Croatian dia-
betologists generally follow the American Association 
of Clinical Endocrinologists (AACE) and National 
Institute for Health and Clinical Excellence (NICE) 
guidance in selecting patients for pump treatment. 
Patient Population
During a 5-year period (2009-2014), 164 patients 
with type 1 diabetes were monitored at the Depart-
ment of Endocrinology, Clinical Department of In-
ternal Medicine, Zagreb University Hospital Center. 
The proportion of patients diagnosed in adult age was 
52%. For the remaining 48% that developed diabetes 
in childhood, transition from a pediatric diabetologist 
to adult one was performed. Over a 5-day period, 84 
patients attended a structured education program that 
included daily consultations with a multidisciplinary 
healthcare team. The team was led by an endocrinolo-
gist-diabetologist and included a nurse-educator, nu-
tritionist, physical medicine specialist and psychiatrist 
who provided psychological support. Of the 164 pa-
tients, 26 (15%) patients (eight male and 18 female) 
were treated with insulin pump. All of them went 
through the structured (re)education program. They 
were subsequently capable of self-management in ad-
ministering both multiple daily injections, instructed 
for optimal usage of CSII technology and taught to 
count carbohydrates and determine insulin doses cor-
rectly. Five patients started using CSII before the age 
of 18 at Clinical Department of Pediatrics, whereas 
21 adult patients did the same at the Department of 
Endocrinology. The median age when commencing 
pump therapy was 27 (age range 21-39) years. Five 
patients had chronic complications, i.e. retinopathy 
in two, polyneuropathy in one, and both nephropathy 
and retinopathy in two patients. 
Data on 21 patients previously treated with mul-
tiple daily injections who commenced insulin pump 
therapy in adulthood were retrospectively analyzed. 
Finally, 20 patients were analyzed because one of 
them had started insulin pump therapy only recently 
and had no closing data. Data were analyzed using 
descriptive statistics, after which nonparametric Wil-
coxon signed-rank test and correlation analysis were 
performed. Statistical analysis was performed using 
SPSS 15.0 (SPSS, Chicago, IL, USA), with the level 
of statistical significance set at p<0.05.
Results
The median HbA1c upon commencing insulin 
pump therapy was 6.95% (5.3%-11.4%). After 1 year 
± 3 months of CSII therapy, the median HbA1c was 
6.5% (4.9%-8.4%). The Wilcoxon signed-rank test 
(p=0.0006) confirmed a statistically significant differ-
ence between the initial median and one-year value of 
HbA1c.
The indication for insulin pump therapy was de-
termined by the diabetologist-endocrinologist on the 
basis of personal judgment, and documented in the pa-
tient’s medical records. There were four main indica-
tion groups for CSII: 1) frequent and/or severe hypo-
glycemia; 2) specific lifestyle, e.g., shift work, sports; 3) 
the patient did not reach glycemic goals despite adher-
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ence and/or labile diabetes; and 4) preconception, e.g., 
planned pregnancy with expected complications. 
A patient could meet more than one criterion. The 
most frequent indication was hypoglycemia found in 
57% of cases, followed by specific lifestyle indication 
47%, failure to reach glycemic goals despite good com-
pliance in 29% of patients, and planned pregnancy with 
expected complications in 29% of female patients. 
Initial occurrence of hypoglycemia was analyzed 
using 6-day continuous glucose monitoring. The next 
evaluation took place after one year with the hypogly-
cemia incidence estimated using history data. The ini-
tial median number of hypoglycemic events during the 
6 days was 5 (0-6) in all patients. Hypoglycemic events 
that occurred during the night were expressed in per-
centages with an initial median value of 30% (0-100%). 
After one year, 20 patients were analyzed again. The 
second evaluation resulted in a median value of 1 (0-7) 
hypoglycemic event during a 6-day period, with 0% of 
all hypoglycemias being nocturnal. The total number 
of hypoglycemias was significantly lower after one year 
(p=0.000). The median percentage of nocturnal hypo-
glycemia after one year of CSII therapy was 0. There 
was no correlation between the initial level of HbA1c 
and the number of hypoglycemias (Spearman’s rank 
correlation coefficient was equivalent to -0.3, p value 
in the test was not significant, p=0.392), and after one 
year there was no significant correlation (Spearman’s 
rank correlation coefficient was equivalent to -0.18, 
p=0.307).
Eleven patients that commenced insulin pump 
therapy due to an indication of hypoglycemia were 
analyzed separately. Upon commencing pump therapy, 
their median HbA1c was 6.7% (5.3%-9.4%), with a 
median of 7 (4-21) hypoglycemias over a period of 6 
days, and a median of 50% (0-100%) nocturnal hypo-
glycemia events. After one year, the median HbA1c 
was 6.0% (4.0-8.4%), and a median of 1 (0-7) hypo-
glycemia in 6 days, again with 0% of all hypoglycemias 
being nocturnal. There was a statistically significant 
difference between the HbA1c value before and after 
CSII therapy (p=0.050), between the initial number of 
hypoglycemic events and their number after one year 
(p=0.003). There was also a statistically significant dif-
ference between the initial number of nocturnal hypo-
glycemic events and the number of nocturnal events 
after one year of CSII therapy (p=0.011).
In nine patients, the indication for insulin pumps 
was a specific lifestyle. Of these, four patients worked 
in shifts, four patients were sporting enthusiasts per-
forming high-intensity exercises on daily basis, and 
one was mother with type 1 diabetes having specific 
needs. Only two of the patients with an indication 
were from the hypoglycemia group. Their initial me-
dian HbA1c was 7.4% (6.8%-11.4%), and after one 
year it decreased to 6.75% (6%-7.8%; p=0.035). 
Six patients did not reach glycemic goals before 
commencing CSII therapy despite good adherence, 
or had brittle diabetes. Three of them also had an in-
dication in the hypoglycemia group, another three of 
these young patents already had chronic complications 
of the disease, two of them suffering from both severe 
kidney disease and retinopathy and one having painful 
polyneuropathy. Two patients had dawn phenomenon, 
one with extreme labile diabetes including frequent 
ketoacidosis and hypos. The initial median value of 
their HbA1c was 8.9% (6%-11.4%), and after one year 
it decreased to 7.14% (6%-8.4%), yielding a statistical-
ly significant difference (p=0.028). The initial median 
value of all hypoglycemic events was 7 (0-20) over a 
6-day period, and after one year it was 1 (0-7) hypo-
glycemia in 6 days, but the difference was not statisti-
cally significant (p=0.068). When analyzing the CSII 
basal rate levels of these patients, large discrepancies of 
insulin needs during various periods of the day became 
apparent.  
Five female patients had an indication for the use 
of insulin pump due to anticipated high-risk planned 
pregnancy (diagnosis such as chronic renal failure 
grade IV with nephritic syndrome, previous intrauter-
ine fetal demise and spontaneous miscarriages, labile 
diabetes with frequent hypoglycemia followed by epi-
leptic seizures, severe retinopathy, and allergic reaction 
to insulin analogues). An indication of hypoglycemia 
was shown in three of these five patients. Five patients 
gave birth (one of them twice, so there were 6 preg-
nancies) and one patient without an initial indication 
of preconception care is currently pregnant. The me-
dian age at conception was 26 (25-31) years. On aver-
age, they wore an insulin pump for 10 months before 
conception. Their initial median HbA1c when initiat-
ing pump therapy was 6.15% (6%-8.9%), at the time 
of conception the median HbA1c was 5.31% and for 
all 6 pregnancies the median HbA1c in the third tri-
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mester was 5.28%. All deliveries were performed using 
elective cesarean section at 38±2 weeks, and only one 
child briefly stayed in the neonatal intensive care unit 
for observational purposes (Apgar 10/7). The median 
weight of the newborns was 3.255 (2.670-4.870) g and 
median length 48.5 (47-55) cm.
Discussion
According to large studies, estimates show that 
5% of type 1 patients optimally treated with multiple 
daily insulin injections suffer from severe hypoglyce-
mia. At least another 5% undergo hypoglycemia to 
such an extent that they experience significant dis-
ability on a daily basis. Furthermore, 15% of type 1 
diabetic patients have elevated HbA1c with extensive 
fluctuations in blood glucose and unpredictable, mod-
erate hypoglycemia. A small proportion of these have 
dawn phenomenon9-12. Presumably, 15%-20% of type 
1 patients would significantly benefit from the use of 
insulin pump13, with a similar percentage of 12% as 
suggested by the NICE TA151 guidelines14.
If patients have the option of deciding for themselves 
whether to take CSII therapy without primary medical 
indication, the number could be much bigger. The per-
centage of pump users among type 1 diabetics differs 
significantly among countries15. The highest incidence 
is in the USA (37.8% in 2009, significantly higher than 
17% five years earlier)16. It should also be noted that, 
although NICE estimates the need of pump therapy in 
12% of type 1 diabetics, a 2011 audit in the UK revealed 
that there were significantly less (around 6%) users17. In 
Croatia during 2013, there were approximately 16,800 
adult type 1 diabetic patients1. In October 2014, there 
were 611 insulin pumps in use for both pediatric and 
adult type 1 diabetics, yielding approximately 3.4% (in-
cluding around 1000 children with type 1 diabetes) of 
patients with type 1 diabetes treated with CSII thera-
py. However, there is the issue of estimating the actual 
number of persons with type 1 diabetes. For example, 
the Swedish National Diabetes Registry has reported 
18,168 persons with type 1 diabetes (15% of them pump 
users)18 in a country with a population roughly double 
that of Croatia (9,640,000 vs. 4,290,000). The Swedish 
Registry considers type 1 insulin-requiring diabetes the 
one appearing before the age of 35. The Croatian Reg-
istry does not specify the age at onset. 
At Department of Endocrinology, Clinical De-
partment of Internal Medicine, Zagreb University 
Hospital Center, 15% of adult type 1 diabetic subjects 
were treated with insulin pumps. This fact confirms the 
above IDF statement about the disproportionate use 
of insulin pumps across the country2. 
An essential indication for the use of CSII is hypo-
glycemia, a side effect of the life-saving insulin therapy. 
Hypoglycemias occur even when insulin is administered 
in the best possible manner using multiple daily injec-
tions, analogues and pens in a compliant and trained 
patient. Other indications for CSII are of great impor-
tance for everyday life, although they are not immedi-
ately threatening; however, they are threatening at long 
term due to the inability to reach the HbA1c target 
and prevent the onset of chronic complications. Some 
indications are a matter of personal choice (shift work, 
sports, or pregnancy planning). Hypoglycemic events 
are noted in all guidelines as a key indication for CSII 
therapy6,14,19. When taking this into consideration, it is 
no wonder that a diabetologist’s personal judgment in 
most indications for CSII includes hypoglycemia. 
In all study patients, there was a significantly lower 
incidence of hypoglycemia after one year of insulin 
pump therapy (5 events in 6 days vs. 1 event in 6 days), 
along with a significantly lower HbA1c (6.95% at the 
beginning vs. 6.5% after one year). Their initial HbA1c 
showed a weak negative correlation with hypoglyce-
mic events, confirming that some diabetic patients are 
prone to hypoglycemia despite more flexible HbA1c 
goals (the mean HbA1c upon commencing pump use 
was not very low), e.g., some of the patients had severe 
and frequent hypoglycemia despite undergoing subop-
timal glycemic control. 
The group of patients with hypoglycemia as a spe-
cific indication for insulin pump had about 7 hypogly-
cemic events in 6 days, with about 50% of them being 
nocturnal. They actually had a hypoglycemic event ev-
ery other night. After one year of therapy, hypoglyce-
mic events became rare (1 event in 6 days), and virtually 
no nocturnal events. This was accompanied by a strict 
goal of HbA1c value of 6.0%. A typical patient with 
type 1 suffers on average two episodes of symptomatic 
hypoglycemia per week, and one episode of severe hy-
poglycemia per year20.  After one year of CSII, patients 
that had previously had frequent hypoglycemic events 
became ‘average type 1 patients’. 
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The lifestyle indication is not a crucial one, and the 
consequences of insulin pump therapy are not easy 
to describe in numbers alone. Physical activity is ex-
tremely important for some young patients with type 
1 diabetes mellitus. Survey of a small group of 28 pa-
tients completing 5 days of structured education at the 
Department of Endocrinology, Clinical Department of 
Internal Medicine, Zagreb University Hospital Cen-
ter, showed that 87.5% of patients undergoing mod-
erate to high intensity activities achieved a minimum 
of  600-1500 MET (Metabolic Equivalent of Task) 
minutes/week as scored by the International Physical 
Activity Questionnaire (IPAQ)21. Two patients man-
aged to go bike riding from the northern to the south-
ern end of the Croatian coast, cycling about 850 km 
with no hypoglycemia, ketoacidosis or larger glycemic 
excursions. One of the patients had a lifestyle indica-
tion and was a medical doctor working shifts in the 
emergency ward 3-5 times a month. Another patient 
was a nurse working a similar schedule and did not ex-
perience any larger excursions. One of the patients was 
mother of a child with type 1 diabetes, experiencing 
frequent nocturnal glycemic excursions. After one year 
of CSII therapy, these patients had no hypoglycemia, 
but most important is that they were able to perform 
their duties and physical exercises almost without any 
limitations posed by diabetes, and experienced HbA1c 
improvement (7.4% vs. 6.75%).
For patients who did not reach the glycemic goal 
with multiple daily injections, or had labile diabe-
tes, insulin pump was also a good choice. Their final 
HbA1c was 7.14% as a result of frequent diurnal basal 
rate fluctuations, whereas such variations were not 
possible using conventional therapy.
The last indication for CSII was planned pregnancy 
in association with some anticipated complications not 
necessarily related to diabetes. The outcome of such a 
high-risk pregnancy is not easy to predict. A recent 
multicenter study in women using insulin pumps dur-
ing pregnancy, just like in our small group, indicated a 
lower HbA1c without an increased risk of severe hy-
poglycemia22. All the patients wore insulin pump be-
fore becoming pregnant and started their pregnancy 
well prepared (were well educated and informed about 
lower targets). The preconception HbA1c was 5.31%, 
and in the third trimester it was of a similar value of 
5.28%, with a low incidence of hypoglycemia. The gen-
eral result of other pregnancy outcomes is not possible 
to statistically evaluate in only 6 cases; however, in 
those pregnancies CSII therapy was effective and safe. 
Conclusion
Despite administering insulin basal bolus therapy 
using multiple daily injections, insulin analogues, pens, 
undergoing intensive education and re-education, hy-
poglycemia is still a major clinical problem for patients 
with type 1 diabetes. While awaiting the development 
of other therapeutic choices, insulin pump provides an 
effective option for patients experiencing severe, fre-
quent hypoglycemic events, especially nocturnal ones. 
For patients with a specific lifestyle, CSII alleviates 
the limitation set by insulin dependent diabetes. For 
those who do not reach glycemic targets or have labile 
diabetes, insulin pump can improve glycemic control. 
In pregnant women with type 1 diabetes, it provides a 
safe way to adhere strictly to glycemic targets. 
The modest experience acquired in our center con-
firms that hypoglycemia is the major reason for pump 
therapy. All patients improved their blood glucose 
regulation, indicating that the current patient selection 
process seems to work. However, local guidelines on 
further development would be of help. Additionally, 
reimbursement policy as well as education for patients 
and professionals could help overcome the dispropor-
tional use of pumps in various parts of the country.
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Sažetak
NOĆNA HIPOGLIKEMIJA – VODEĆA INDIKACIJA ZA TERAPIJU INZULINSKOM CRPKOM U 
ODRASLIH 
M. Baretić, I. Kraljević i I. Pavlić Renar
Cilj studije bio je istražiti koji su odrasli bolesnici s tipom 1 dijabetesa liječeni s više dnevnih doza inzulina najbolji 
kandidati za liječenje inzulinskom crpkom, uzimajući u obzir njihovu ograničenu dostupnost  u Republici Hrvatskoj. Na 
Zavodu za endokrinologiju Interne klinike Kliničkoga bolničkog centra Zagreb praćeno je 145 bolesnika s tipom 1 dija-
betesa (kod 52% njih je bolest dijagnosticirana u odrasloj dobi) u razdoblju od 2009. do 2014. godine. Kod 21 bolesnika (7 
muškaraca i  14 žena, medijan dobi 27 godina) liječenje crpkom započelo je u odrasloj dobi. Petoro bolesnika je imalo kro-
nične komplikacije (dvoje retinopatiju, jedan polineuropatiju,  a dvoje je imalo i retinopatiju i neuropatiju). Medijan HbA1c 
prije započinjanja liječenja inzulinskom crpkom je bio  6,95%, a nakon godine dana terapije crpkom 6,5%. Bolesnici su 
bili razvrstani prema indikaciji za liječenje crpkom (učestale i/ili teške hipoglikemije, specifičan stil života, nepostizanje 
željenih ciljeva glikemije unatoč suradljivosti/nestabilan dijabetes te pretkoncepcija). Bolesnici su mogli ispunjavati i više 
od jedne indikacije. Na početku liječenja učestalost hipoglikemija se analizirala kontinuiranim praćenjem glukoze tijekom 
5-6 dana, a reevaluacija je učinjena iz anamnestičkih podataka nakon 1 godine ± 3 mjeseca. Na samom početku liječenja 
bolesnici su imali 5 hipoglikemija/6 dana  (30% noćnih), a nakon godine dana 1 hipoglikemiju/6 dana (bez noćnih). Wil-
coxonov signed-rank test pokazao je statistički značajnu razliku u broju i učestalosti noćnih hipoglikemija te u HbA1c. Kod 
onih bolesnika u kojih je liječenje započelo inzulinskom crpkom s indikacijom hipoglikemije prije crpke medijan HbA1c 
je bio 6,7% sa 7 hipoglikemija/6 dana (50% noćnih). Nakon godinu dana medijan HbA1c je bio 6% s 1 hipoglikemijom 
/6 dana (bez noćnih). Kao zaključak, vodeća indikacija za liječenje inzulinskom crpkom u odraslih bolesnika je učestalost 
hipoglikemija, osobito noćnih.
Ključne riječi: Dijabetes melitus, tip 1 – komplikacije; ; Hipoglikemija – prevencija i kontrola; Inzulin – primjena i doziranje; 
Inzulin, sustavi za infuziju; Inzulinska crpka; Odrasla osoba
